Pfizer Inc. (NYSE:PFE) shares, rose in value on Wednesday, 07/21/21, with the stock price down by -0.07% to the previous day’s close as strong demand from buyers drove the stock to $41.02.
Actively observing the price movement in the last trading, the stock closed the session at $41.05, falling within a range of $40.515 and $41.24. The value of beta (5-year monthly) was 0.68 whereas the PE ratio was 24.62 over 12-month period. Referring to stock’s 52-week performance, its high was $43.08, and the low was $32.79. On the whole, PFE has fluctuated by 4.06% over the past month.
With the market capitalization of Pfizer Inc. currently standing at about $228.14 billion, investors are eagerly awaiting this quarter’s results, scheduled for Jul 28, 2021. The company’s Forward Dividend Ratio is 1.56, with its dividend yield at 3.80%. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0.96, which is expected to increase to $1.14 for fiscal year $3.7 and then to about $3.42 by fiscal year 2022. Data indicates that the EPS growth is expected to be 66.70% in 2022, while the next year’s EPS growth is forecast to be -7.60%.
Analysts have estimated the company’s revenue for the quarter at $18.45 billion, with a low estimate of $14.63 billion and a high estimate of $23.1 billion. According to the average forecast, sales growth in current quarter could jump up 59.70%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $72.78 billion, representing an increase of 73.70% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 2 upward and no downward review(s) in last seven days. We see that PFE’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
21 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 16 analyst(s), 4 recommend it as a Buy and 1 called the PFE stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Hold.
The stock’s technical analysis shows that the PEG ratio is about 2.14, with the price of PFE currently trading nearly 3.59% and 3.76% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 67.45, while the 7-day volatility ratio is showing 1.82% which for the 30-day chart, stands at 1.32%. Furthermore, Pfizer Inc. (PFE)’s beta value is 0.72, and its average true range (ATR) is 0.60. The company’s stock has been forecasted to trade at an average price of $43.08 over the course of the next 52 weeks, with a low of $39.00 and a high of $53.00. Based on these price targets, the low is 4.92% off current price, whereas the price has to move -29.21% to reach the yearly target high. Additionally, analysts’ median price of $42.70 is likely to be welcomed by investors because it represents a decrease of -4.1% from the current levels.
A comparison of Pfizer Inc. (PFE) with its peers suggests the former has fared considerably weaker in the market. PFE showed an intraday change of -0.07% in last session, and over the past year, it grew by 17.97%%. In comparison, Eli Lilly and Company (LLY) has moved higher at 0.97% on the day and was up 43.55% over the past 12 months. On the other hand, the price of AstraZeneca PLC (AZN) has risen 0.40% on the day. The stock, however, is off -0.52% from where it was a year ago. Additionally, there is a gain of 0.62% for Johnson & Johnson (JNJ) in last trading while the stock has seen an overall depriciation of 13.19%% over the past year. The PE ratio stands at 24.62 for Pfizer Inc., compared to 35.54 for Eli Lilly and Company, and 38.21 for AstraZeneca PLC. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 0.82%. Meanwhile, the Dow Jones Industrial Improved by 0.83%.
Data on historical trading for Pfizer Inc. (NYSE:PFE) indicates that the trading volumes over the past 3 months, they’ve averaged 25.31 million. According to company’s latest data on outstanding shares, there are 5.60 billion shares outstanding.
Nearly 0.04% of Pfizer Inc.’s shares belong to company insiders and institutional investors own 66.70% of the company’s shares. The stock has risen by 11.44% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PFE stock heading into the next quarter.